Relaxin is a potent, reversible inhibitor of spontaneous uterine contractions in a number of species, including rats, mice, gui nea\x=req-\ pigs, rabbits, sheep and pigs, in vivo and in vitro. The potency of relaxin on the isolated uterus is about 1\p=n-\5nmol l \m=-\1 (assuming a molecular mass of 6 kDa; Table 1); relaxin is therefore one of the most potent uterine relaxants known. The isolated human uterus, however, has been reported to be relatively insensitive to relaxin. Human recombinant relaxin has only recently become available and, therefore, in this review it may be assumed that the studies described were conducted using porcine relaxin unless stated otherwise. Low doses of relaxin selectively reduce the frequency of contractions in rats in vivo and at high doses complete inhibition of myometrial contractions is achieved Hollingsworth, 1991, 1992a). The duration of inhibition is related to the dose of relaxin administered. Relaxin has a rapid onset of action in vivo (within 1-2 min of adminis¬ tration of an intravenous dose) and recovery of uterine contrac¬ tions to control values occurs rapidly after clearance of relaxin from the circulation. The half-life of endogenous relaxin in the circulation of the mid-and late-pregnant rat is 80 and 50 min, respectively (Sherwood el al., 1984) and human relaxin shows half-lifes of 15 and 60 min for the second and third decay phases in the rat, respectively (Cossum et al., 1992). Similarly, in vitro, uterine contractions are inhibited rapidly upon addition of relaxin to the tissue bath (Wiqvist and Paul, 1958; Bradshaw et al., 1981; Anderson, 1984), and recovery of uterine contractions occurs after relaxin is washed from the bathing medium. Collectively these observations suggest that relaxin inter¬ acts with a plasma membrane receptor in the myometrium.